WO2006061925A1 - フリーラジカル疾患予防治療用組成物 - Google Patents
フリーラジカル疾患予防治療用組成物 Download PDFInfo
- Publication number
- WO2006061925A1 WO2006061925A1 PCT/JP2005/014798 JP2005014798W WO2006061925A1 WO 2006061925 A1 WO2006061925 A1 WO 2006061925A1 JP 2005014798 W JP2005014798 W JP 2005014798W WO 2006061925 A1 WO2006061925 A1 WO 2006061925A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- fullerene
- free radical
- composition
- disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/44—Elemental carbon, e.g. charcoal, carbon black
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B15/00—Single-crystal growth by pulling from a melt, e.g. Czochralski method
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
- H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
- H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer
- H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having at least one potential-jump barrier or surface barrier, e.g. PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic System or AIIIBV compounds with or without impurities, e.g. doping materials
- H01L21/20—Deposition of semiconductor materials on a substrate, e.g. epitaxial growth solid phase epitaxy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Definitions
- the present invention relates to a composition for the prevention and treatment of free radical diseases, which exhibits high preventive and therapeutic efficacy against various free radical-related diseases, and has high drug stability and low side effects in vivo. It is. Background art
- Fullerene molecules are composed of carbon atoms, and each sphere contains 32 to 100 or more carbon atoms.
- fullerenes see: (i) RE Sialley, “One Beam of Ultrasonic Carbon Cluster in Atomic and Molecular Classes”, E. LBerstein Ed., Physical theory chemistry, Vol. 68, Else Beer'Science (New York), pp. 1-68 (1990), (ii) F. Curl et al., “Fullerenes”, Scienti Fick American, pages 32 to 41 (October 1991), (iii) F.
- fullerenes The most typical of these fullerenes is C 60 fullerene. And its structure is reminiscent of football. There are other fullerenes, especially C70 and C84 as higher fullerenes. And fullerenes are now commonly known as “buckyballs”. C60 fullerene molecules generally contain small amounts of C70 fullerene and C84 fullerene as impurities. The preparation of fullerenes and their solubility, crystallinity and color properties are described in many literatures, especially in the paper by W. Kraetschmer et al. [Nature, 347, 354-358 (1990) ), And Chemical 'and' Engineering 'News, pages 22-25 (October 1990)].
- fullerenes With increasing interest in fullerenes, the application of fullerenes to pharmaceuticals and cosmetics has been studied and specific proposals have been made. For example, blending fullerenes or fullerene mixtures into cosmetics (Patent Document 1), making a cosmetic composition for suncare using the ultraviolet absorption effect of fullerenes (Patent Document 2), and using fullerene as a photosensitizer.
- the present inventors have proposed a method of optically inactivating viruses (Patent Document 3) and applying fullerene as an antioxidant to external preparations for skin (Patent Document 4).
- Non-patent Documents 1 and 2 diseases caused by in vivo free radicals (in the present invention, It has been pointed out that this is called free radical disease (Non-patent Documents 1 and 2). In fact, for the purpose of treating or preventing these free radical diseases, the development of drugs for the prevention and treatment of free radical diseases has been promoted for a long time, and many pharmaceutical ingredients such as the following have already been proposed. Yes.
- Non-patent Document 3 SOD-related substances (Non-patent Document 3), ubiquinone preparations (Patent Document 5), benzozevin derivatives (Patent Document 6), pyrrolidinone derivatives (Patent Document 7), substituted vinyl derivatives (Patent Document 8), oxamide derivatives (Patent Document 9), Furan Carpoxamide Derivative (Patent Document 10), Phthalimide Derivative (Patent Document 11), Docosahexaenoic Acid (Patent Document 12), Linolenic Acid Derivative (Patent Document 13) , Quinolinoxide derivatives (patent document 14), heteroaromatic amine derivatives (patent document 15), carbostyryl derivatives (patent document 16), isoindole derivatives (patent document 17), cell product (patent document) 1 8), imidazol thione carboxamide derivative (Patent Document 19), dipenzoxepin derivative (Patent Document 20), propylamine derivative (P
- the present invention is based on the present inventors' previous knowledge that fullerene is applied to a topical skin preparation as an antioxidant, and the above-mentioned conventional drugs for prevention and treatment of free radical diseases as described above.
- the problem is to provide a new composition for the prevention and treatment of free radical diseases that eliminates the problems associated with drugs, has few side effects, has high free radical scavenging activity in the body, and has excellent pharmaceutical stability. Yes.
- Patent Document 1 Japanese Patent Laid-Open No. 6-1 9 2 0 39
- Patent Document 2 Japanese Patent Laid-Open No. 9-2 7 8 6 2 5
- Patent Document 3 JP-A-9-3 2 2 7 6 7
- Patent Document 4 Japanese Patent Application Laid-Open No. 2004-2 5 0 6 90
- Patent Document 5 Japanese Patent Application Laid-Open No. Sho 5 71 4 2 6 1 6
- Patent Document 6 Japanese Patent Laid-Open No. Sho 5 7-1 9 3 4 6 2
- Patent Document 7 Japanese Patent Laid-Open No. 5-9-2 7 8 2 3
- Patent Document 8 Japanese Patent Application Laid-Open No. 60-0 2 8 96 3
- Patent Document 9 Japanese Laid-Open Patent Publication No. 5-9 1 6 3 3 5 3
- Patent Document 10 Japanese Patent Application Laid-Open No. 5 9-1 9 09 9 1
- Patent Document 11 Japanese Patent Application Laid-Open No. 6 1-3 7 7 6 6
- Patent Document 1 2 Japanese Patent Laid-Open No. 4-2 7 3 8 1 7 Patent Document 13: Japanese Patent Laid-Open No. 61-44853
- Patent Document 14 Japanese Patent Laid-Open No. Sho 6 1-1 6 5869
- Patent Document 15 Japanese Patent Application Laid-Open No. Sho 6 1 1 2 82377
- Patent Document 16 Japanese Patent Application Laid-Open No. Sho 63 1 3 0182 1
- Patent Document 17 Japanese Patent Laid-Open No. Sho 631-150276
- Patent Document 18 Japanese Patent Laid-Open No. 1-14 3868
- Patent Document 19 Japanese Patent Laid-Open No. 11-6820
- Patent Document 20 Japanese Patent Laid-Open No. 3-176487
- Patent Document 21 Japanese Patent Laid-Open No. 3-23 6378
- Patent Document 22 Japanese Patent Laid-Open No. 4-2 1 1666
- Patent Document 23 Japanese Patent Laid-Open No. 11-25726
- Patent Document 24 Japanese Patent Laid-Open No. Hei 41-330088
- Patent Document 25 Japanese Patent Laid-Open No. 54-4401
- Patent Document 26 Japanese Patent Laid-Open No. 2-30 8799
- Patent Document 27 Japanese Patent Laid-Open No. 4 1 3 1 2531
- Patent Document ⁇ 28 Japanese Patent Laid-Open No. 6-72 871
- Patent Document 29 Japanese Patent Laid-Open No. 6-107693
- Patent Document 30 JP-A-8-29 1075
- Patent Document 31 Japanese Patent Application Laid-Open No. Hei 10 1 3 3026 1
- Non-Patent Document 1 “Reactive Oxygen and Pathology” edited by Inoue, JS
- Non-patent document 2 “Antioxidant”: Futaki et al.
- Non-Patent Document 3 Inoue, et al., Biochemistry, 28, 66
- the present inventor has used vascular endothelial cells in vitro as an adult disease model.
- free radicals were generated by culturing and temporarily hypoxic, and fullerenes were allowed to act on them, it was confirmed that free radicals generated in cells were suppressed more than conventional vitamin C.
- fullerenes have significantly better stability, are less toxic in vivo, and can fully exert their effects, thereby completing the present invention.
- composition for preventing and treating free radical disease of the present invention is characterized by the following as a solution to the above problems.
- a composition for the prevention and treatment of free radical diseases comprising as an active ingredient at least one of fullerene, a fullerene derivative, or a fullerene modified or clathrated with an organic compound or a complex of fullerene derivatives. .
- the fullerene derivative is a fullerene that combines one or more of an oxygen-containing group, a nitrogen-containing group, and an optionally substituted hydrocarbon group.
- the first composition for preventing and treating free radical diseases object is a fullerene that combines one or more of an oxygen-containing group, a nitrogen-containing group, and an optionally substituted hydrocarbon group.
- the first composition for preventing and treating free radical disease wherein the fullerene is at least one selected from fullerene multimers, carbon nanotubes, derivatives thereof, and salts thereof.
- the first composition for preventing and treating free radical disease wherein the fullerene is at least one selected from a fullerene cleavage product, a fullerene fragment, a derivative thereof, and a salt thereof.
- Fullerenes are complexes of one or more of fullerenes and fullerene derivatives with one or more of organic oligomers, organic polymers, cyclodextrins and crown ethers and one or more of the related compounds.
- the composition for the prevention and treatment of any free radical disease is a complex of at least one of fullerene and fullerene derivatives and polyvinylpyrrolidone (PVP).
- composition for preventing and treating free radical disease according to any one of the first to fifth, wherein the fullerene is represented by the following formula.
- F is a fullerene represented by C n (C is a carbon atom, n is an integer of 3 or more), carbon nanotubes, and their multimers, cleaved bodies, split bodies, or a mixture thereof.
- R im is m substituents bonded to C n, and each independently or independently represents a hydroxyl group, an ester group of the hydroxyl group and an inorganic acid or an organic acid, and a coordination of the hydroxyl group and a sugar.
- a saccharide group, a ketal group of its hydroxyl group and ketone, or an acetal group of its hydroxyl group and aldehyde R 2 m are m atoms bonded to C n, each independently being the same or Otherwise, or indicates that one atom is bonded to two or more different carbons, m represents 0 or an integer of 1 or more.
- C is a fullerene partial structure represented by a carbon atom, and it is sufficient that two or more carbon atoms are covalently bonded (if there is a carbon that is not covalently bonded, Even if there is no indication of R n, it will combine with R n Rn is n substituents bonded to C, and each independently or independently, a hydrogen atom, a carbon atom, an oxygen atom, a nitrogen atom, a phosphorus atom, a hydroxyl group, It represents an ester group of a hydroxyl group and an inorganic acid or an organic acid, a glycoside group of the hydroxyl group and a sugar, a ketyl group of the hydroxyl group and a ketone, or an acetal group of the hydroxyl group and an aldehyde.
- n represents an integer of 0 or 1 or more.
- composition for preventing or treating free radical diseases according to any one of the first to ninth, further comprising at least one antitumor agent.
- Anti-tumor agents include nitromine (R), cyclophosphamide, melphalan, thiotepa, force lupocon, Protecton (R), busulfan, dimustine hydrochloride, mitopurinitor, ifosfamide, mercaptopurin, thioinosine, Cytarabine, Dagarpazine, Fluorouracil, Tegafur, Anshiyubo hydrochloride, Methotrexate, Carmofur, UF T (R), Enoshibabin, Binplastin sulfate, Vincristine sulfate, Vindesine sulfate, Actinomycin (D), Mitomycin (:, Chromo Mycin A3, Bleomycin Hydrochloride, Bleomycin Sulfate, Daunorubicin Hydrochloride, Doxorubicin Hydrochloride, Neocarcinos Yuchin, Bepeptibromycin Sulfate, Acralubicin Hydro
- No. 12 Free radical disease, myocardial infarction, ischemic heart disease, heart failure, angina, arrhythmia, arteriosclerosis, liver lipid metabolism disorder, hyperlipidemia, essential hypertension Pressure, hypertension, arteriosclerosis, coronary arteriosclerosis, thrombosis, obstructive arteriosclerosis, vascular disorder, peripheral vascular disorder, cholestasis, hypercholesterolemia, knee disorder, organ failure, acute chronic hepatitis, Gastric ulcer, duodenal ulcer, ulcerative colitis, extinct organ disorder, cholecystosis, diabetes, arthritis treatment, rheumatism, liver failure, liver disorder, ischemic liver disorder, liver lipid metabolism disorder, gallbladder disorder, organ transplant disorder, sugar Urine disease, toxicosis, organ transplant disorder, cancer, ischemic reperfusion injury, tissue aging, skin tissue pigmentation, skin tissue fistula, alveolar pus leakage, skin tissue seborrhea, skin tissue sunburn, A composition for the prevention and
- Cancer is malignant melanoma, malignant lymphoma, digestive cancer, lung cancer, esophageal cancer, stomach cancer, colon cancer, rectal cancer, colon cancer, ureteral tumor, gallbladder cancer, bile duct cancer, biliary tract cancer, breast cancer, liver Cancer, knee cancer, testicular tumor, maxillary cancer, tongue cancer, lip cancer, oral cancer, pharyngeal cancer, laryngeal cancer, ovarian cancer, uterine cancer, prostate cancer, thyroid cancer, brain tumor, force positive sarcoma, hemangioma, leukemia
- the composition for preventing and treating free radical disease according to the above-mentioned 12, which is polycythemia vera, neuroblastoma, retinoblastoma, myeloma, cystoma, sarcoma, osteosarcoma, or myoma.
- Ischemic reperfusion injury ischemic heart disease, ischemic reperfusion myocardial injury, ischemic liver injury, ischemic reperfusion liver injury, ischemic reperfusion kidney injury, ischemic reperfusion knee injury, Ischemic reperfusion gallbladder disorder, ischemic reperfusion cardiovascular disorder, ischemic reperfusion gastrointestinal disorder, ischemic reperfusion myopathy, ischemic reperfusion vascular disorder, ischemic reperfusion ocular disorder, or ischemic reperfusion 12.
- the composition for preventing and treating free radical disease according to the above-mentioned first or second, which is a skin disorder.
- Item 17 The composition for preventing and treating free radical disease according to Item 12 above, wherein the infectious disease is a bacterial infection, a viral infection, a fungal infection, or a parasitic infection.
- No. 18 The composition for preventing and treating free radical disease according to No. 17 above, wherein the viral infection is hepatitis, acquired immune deficiency syndrome (AIDS), cold, or influenza. Brief Description of Drawings
- FIG. 1 is a diagram illustrating the effect of PVP / fullerene in suppressing metastasis of skin cancer in Test Example 5.
- FIG. 2 is a diagram exemplifying the effect of suppressing metastasis of cancer cells by PVP / fullerene in Test Example 6.
- the active ingredient or useful ingredient is the fullerene as described above, which is modified or clathrated with fullerene, a fullerene oxygen-containing derivative, and an organic compound. It consists of at least one of the above fullerenes or fullerene oxygen-containing derivatives and their salts.
- fullerenes are expressed as C n (n is an integer of 60 or more), including C 60, C 70, or a mixture thereof, and carbon tube fullerenes, etc.
- Various types including a conventionally known one having a carbon skeleton structure such as a spherical shape or a tube may be used.
- the fullerene of the invention of this application includes a combination of a plurality of fullerenes via an alkylene chain such as a methyle chain, or an alkylene chain bonded to carbon atoms at different positions of the fullerene skeleton. It may be a combination.
- 1 to 40 modifying groups may be bonded to one fullerene molecule.
- a modifying group is bonded to one fullerene molecule.
- 1 to 50 may be bonded to each other, and each of these modifying groups is independently a hydroxyl group, an ester group of the hydroxyl group with an inorganic or organic acid, or a glycoside group with a sugar, or a hydroxyl group. It may be a ketal group with a ketone or an acetal group with an aldehyde, and may be at least one selected from the fullerene-modified compound or a salt thereof.
- fullerene of the invention of this application may be C 60 fullerene, C 70 fullerene or nanotube fullerene, or a mixture of one or more selected from them.
- the fullerene in which a car pump rack (a soot containing a fullerene) as a fullerene powder product remains may be used as long as the concentration of carbon black in the fullerene is 0 to 98% by weight.
- the fullerenes of the invention of this application include various substituents in such a carbon skeleton structure, for example, a hydrocarbon group, an oxygen crosslinking group, a hydroxyl group, an acyl group, an ether, which may have a substituent. Also included are fullerene derivatives having an oxygen-containing group such as a group, a strong lpoxyl group, a nitrogen-containing group such as an amino group or a cyan group.
- fullerene oxygen-containing derivative one in which an oxygen atom is bonded directly to a carbon atom of a fullerene skeleton or via a carbon chain such as an alkylene chain is considered.
- fullerene hydroxide having a direct bonding of —OH groups up to a hydroxylation rate of about 50 / mol fullerene.
- fullerenes that can be used in the present invention, fullerenes represented by the following chemical formulas can be used.
- R im is m substituents bonded to Cn, each independently or independently of a hydroxyl group, an ester group of the hydroxyl group and an inorganic acid or an organic acid, It represents a glycoside group of a hydroxyl group and a sugar, a ketal group of the hydroxyl group and a ketone, or an acetal group of the hydroxyl group and an aldehyde.
- R 2m is m atoms bonded to Cn, and each independently represents the same or different, or one atom bonded to two or more different carbons. m represents 0 or an integer of 1 or more.
- the fullerenes that can be used in the present invention are one or more simple substances or mixtures selected from fullerene multimers, force-bonnanotubes, derivatives thereof, and salts thereof, and organication that modifies or includes them. A compound may be used.
- fullerene multimers include those represented by the following formula. That is, put Komatsu et groups cyanide and flour ⁇ iron ball of Kyoto force capsule steel was successfully synthesized giving fast vibration per minute 3500 times, dimer C 60 (C I2Q;) , And trimers (C 180, below), C 62 synthesized by Rubin et al., Fullerene nitrogen atom synthesized by Wudl et al. (C 59 N) 2 , etc.
- fullerene derivatives that can be used in the present invention include C 6D F and C 6D F 18 in which fluorine is allowed to act on fullerene.
- the present invention also includes a metal-encapsulated fullerene (M in the formula represents a metal atom) as shown below, for example, which is synthesized by mixing a metal in the powder of grapheye koji and evaporating it by applying a laser. Can be used.
- M in the formula represents a metal atom
- Specific examples of the metal-encapsulated fullerene that can be used in the present invention include, but are not limited to, scandium, lanthanum, cesium, and titanium-encapsulated fullerene.
- Metal-encapsulated fullerenes ( ⁇ c 60 ) As the fullerenes that can be used in the present invention, for example, atomic-encapsulated fullerenes (the small spheres in the formulas indicate atoms) as shown below.
- fullerenes that can be used in the present invention are selected from fullerene cleavage products, fullerene cleavage products, derivatives thereof and salts thereof.
- cleavage fullerenes examples include open cage fullerenes produced by RuMn et al. And perforated fullerenes synthesized by Komatsu et al.
- the fullerenes that can be used in the present invention include complexes with organic compounds that modify, include, or complex fullerenes.
- organic compound an organic oligomer, an organic polymer, and an inclusion compound or an inclusion compound or a cyclodextrin (CD) capable of forming an inclusion complex, a crown ether, or one or more of those related compounds are suitable. As illustrated.
- organic oligomers and organic polymers include carboxylic acid esters, alcohols, saccharides, polysaccharides, polyhydric alcohols, and polyethylene.
- Polymers of polyalkylene dallicol or polyhydric alcohols such as polyglycol, butylene glycol, polypropylene glycol, polyvinyl alcohol, etc., starch derivatives such as dextran, pullulan, starch, hydroxyethyl starch and hydroxypropyl starch
- Nonionic water-soluble polymers containing alginic acid, hyaluronic acid, chitosan, chitin derivatives, and anionic or cationic derivatives of these polymers and these polymers glycerin and fatty acids, oils, propylene carbonate, Lauryl alcohol, ethoxylated castor oil, polysorbates, and esters or ethers thereof, polymers thereof, polyester polymers thereof, pyrrolidone polymers such as polyvinylpyrrolidone, etc.
- No Saturated alcohol polymers such as esters or ethers and polyoxyethylenepolypropylene block copolymers are preferably bonded to fullerene or a derivative thereof, and may be a mixture of one or more of them.
- various things such as polyalkylene glycols, such as polyethyleneglycol (PEG), polyvinyl pyrrolidone (PVP), are illustrated as a preferable thing.
- PEG polyethyleneglycol
- PVP polyvinyl pyrrolidone
- the average molecular weight is generally preferably about 200 to 100
- the ratio with the fullerene or fullerene-containing oxygen derivative is preferably It is considered that the molar ratio is about 10/1 or less.
- fullerene salts of the invention of this application are selected from, for example, hydroxylated fullerenes, salts of fullerene esters, polyhydroxylated fullerenes, fullerene range esters, fullerene triesters, fullerene polyesters and the like. Often, the salts only need to form physiologically acceptable salts. Examples of these salts include inorganic salts and organic salts.
- These salts include alkali metals (eg, sodium, potassium, etc.) and alkaline earth metals (eg, calcium, magnesium, etc.) Or a salt with an organic base such as trimethylamine, triethylamine, pyridine, picoline, N, N-dibenzylethylenediamine, ethanolamine, diethanolamine, trishydroxymethylaminomethane, dicyclohexylamine, etc. There may be. From the viewpoints of high safety and economy, one or more metal salts selected from sodium, potassium, magnesium, calcium, and aluminum are suitable as the salts of hydroxylated fullerenes and fullerene monoesters. is doing.
- fullerenes that can be used in the present invention include, for example, cyclodextrin as shown in the following formula, porphyrin complex (Jaws porphyrin) synthesized by Boyd et al., Double nanoring cyclophanefullerene complex, Nakamura et al. Also included are fullerene-phenolate derivatives, fullerene-phenyl derivatives Ph 5 C 6 () , fullerene-biphenyl derivatives, etc. Fullerene derivatives that are water-soluble as fullerenes, modified or clathrates with organic compounds, and fullerene salts are highly stable, easily soluble in water, and have an adjustable pH, resulting in low cytotoxicity.
- porphyrin complex Jaws porphyrin
- Double nanoring cyclophanefullerene complex Nakamura et al.
- fullerene-phenolate derivatives fullerene-phenyl derivatives Ph 5 C 6 ()
- fullerenes and polymeric polymers such as PEG (polyethylene glycol), PVP (polovinylpyrrolidone), or modified with CD (cyclodextrin) or inclusion bodies, and monovalent salts are more water-soluble than divalent salts. It is preferable because of its high solubility in water.
- fullerene-PVP, sodium fullerene hydroxide and sodium fullerene esters, and full power of fullerene hydroxide and monoesters are suitable.
- PVP polyvinylpyrrolidone
- the weight average molecular weight (Mw) is in the range of about 3, 00 to 3, 0 0 0, 0 0 0, , 0 0 0 to 1, 5 0 0, 0 0 0 or so are considered to be suitable.
- PVP may be a synthesized product or a commercially available product.
- the fullerene in this case may be a fullerene derivative as described above.
- fullerenes that can be used in the present invention include, for example, cyclodextrin as shown in the following formula, porphyrin complex (Jaws porphyrin) synthesized by Boyd et al., Double nanoring cyclophanefullerene complex, etc. Also included are fullerene-one-phucene derivatives synthesized by Nakamura et al., Fullerene-phenyl derivatives Ph 5 , fullerene-biphenyl derivatives, and the like.
- porphyrin complex Jaws porphyrin
- Double nanoring cyclophanefullerene complex etc.
- fullerene-one-phucene derivatives synthesized by Nakamura et al.
- Fullerene-phenyl derivatives Ph 5 fullerene-biphenyl derivatives, and the like.
- fullerene cyclodexporin inclusion bodies include those in which an oxygen atom is bonded directly to a carbon atom of a fullerene skeleton or via a carbon chain such as an alkylene chain.
- fullerene hydroxide having a hydroxylation rate of 50 nomole fullerene or more and one OH group directly bonded thereto is exemplified.
- the fullerene cleaved body or fragment that can be used in the present invention may be a fullerene cleaved body or split body represented by the following chemical formula, or a simple substance or a complex of a molecule containing the structure.
- C is a fullerene partial structure represented by a carbon atom, and it is sufficient that two or more carbon atoms are covalently bonded (if there is a carbon that is not covalently bonded, R n Even if there is no display of, R n R n is n substituents bonded to C, each independently or independently, a hydrogen atom, a carbon atom, an oxygen atom, a nitrogen atom, a phosphorus atom, a hydroxyl group, It represents an ester group of the hydroxyl group and an inorganic acid or an organic acid, a glycoside group of the hydroxyl group and a sugar, a ketal group of the hydroxyl group and a ketone, or an acetal group of the hydroxyl group and an aldehyde.
- n represents an integer of 0 or 1 or more.
- examples of the split fullerene that can be used in the present invention include corannulene (C 20 H 10 ) having a C 60 fullerene fragment structure as shown in the following formula.
- a long-chain carboxylic acid having 10 or more carbon atoms, or an ester or salt thereof is also effective to contain a long-chain carboxylic acid having 10 or more carbon atoms, or an ester or salt thereof, together with the above-mentioned active ingredients and fullerenes as useful ingredients.
- oil agents, surfactants, pigments, humectants, excipients and bases, cell activators, and the like as described below may be blended.
- the pH varies depending on the pH of the fullerene, the fullerene derivative, the fullerene clathrate compound, or a salt thereof, but usually the pH is 3 to 10 If it is in this range, fullerene and its derivatives can be blended stably, which is preferable.
- ⁇ is the rounded number of pH of a 0.5% by weight aqueous solution of 20 of the fullerene, fullerene derivative, fullerene-modified or clathrate compound, or salt thereof, and ⁇ is 3
- the pH of a stable fullerene topical preparation should be in the range of 3 to 4, and if the pH of ⁇ is 10 or more, it should be pH 9 to 10.
- the pH of the stable fullerene-containing external composition is preferably in the range of 3 to 10.
- free radical diseases include myocardial infarction, ischemic heart disease, heart failure, angina pectoris, arrhythmia, arteriosclerosis, liver lipid metabolism disorder, hyperlipidemia, essential hypertension, hypertension, arteriosclerosis, Coronary sclerosis, thrombosis, obstructive arteriosclerosis, vascular disorder, peripheral blood vessel disorder, cholestasis, hypercholesterolemia, knee disorder, organ failure, acute chronic hepatitis, gastric ulcer, duodenal ulcer, ulcerative colitis Digestive organ disorder, cholecystosis, diabetes, arthritis treatment, rheumatism, liver failure, liver disorder, ischemic liver disorder, liver lipid metabolism disorder, gallbladder disorder, organ transplant disorder, diabetes, poisoning, organ transplant disorder, Cancer, ischemic reperfusion injury
- the composition for preventing and treating free radical disease of the present invention is a mammal (for example, mouse, rat, pig, raccoon dog, fox, cat, rabbit, rabbit, cinnamon) that retains cancer (tumor). , Horses, goats, monkeys, humans), and is effective in prolonging the life of these cancer-bearing animals and suppressing cancer metastasis.
- the cancer to which the free radical disease preventive treatment composition of the present invention is applied includes a tumor, a benign tumor, or a malignant tumor.
- malignant melanoma malignant lymphoma, digestive organ cancer, lung cancer, esophageal cancer, stomach cancer, large intestine cancer, rectal cancer, colon cancer, ureteral tumor, gallbladder cancer, bile duct cancer, biliary tract cancer, breast cancer, liver cancer, knee Visceral cancer, testicular cancer, maxillary cancer, tongue cancer, lip cancer, oral cancer, pharyngeal cancer, laryngeal cancer, ovarian cancer, uterine cancer, prostate cancer, thyroid cancer, brain tumor, force positive sarcoma, hemangioma, leukemia, genuine Also included are polycythemia, neuroblastoma, retinoblastoma, myeloma, cystoma, sarcoma, osteosarcoma, myoma, skin cancer, basal cell cancer, skin appendage cancer, skin metastasis cancer, skin There are also melanomas.
- the composition for preventing and treating free radical disease of the present invention also exerts the effects of cancer treatment and cancer prevention (including metastasis inhibition). Therefore, by further containing one or more antitumor agents, Furthermore, it can enhance the effects of cancer treatment and cancer prevention (including metastasis inhibition).
- this antitumor agent examples include nitromin (R), cyclophosphamide, melphalan, thiotepa, force lupocon, Protecton (R), busulfan, dimustine hydrochloride, mitopuritol, ifosfamide, mercaptopurine, Thioinosine, Shibu Rabin, Dagarvadine, Fluorouracil, Tegafur, Ancitabine hydrochloride, Methotrexate, Carmofur, UFT (R), Enoshiba bin, Bin plastin sulfate, Vincristine sulfate, Vindesine sulfate, Lactinomycin (D), Mitomycin ( :, Chromomycin A3, bleomycin hydrochloride, bleomycin sulfate, daunorubicin hydrochloride, doxorubicin hydrochloride, neocartinostatin, beptibromycin sulfate, a
- the anticancer effect of cancer transfer can be enhanced even when an anticancer agent such as Inferon Ferron obtained by a natural type or genetic engineering technique is used in combination with the active ingredient of the present invention.
- ischemic reperfusion injury which is an application of the composition for preventing and treating free radical disease of the present invention, specifically includes ischemic heart disease, ischemic reperfusion myocardial injury, ischemic liver injury, ischemic Reperfusion liver disorder, ischemic reperfusion kidney disorder, ischemic reperfusion spleen disorder, ischemic reperfusion gallbladder disorder, ischemic reperfusion cardiovascular disorder, ischemic reperfusion gastrointestinal disorder, ischemic reperfusion myopathy There are ischemic reperfusion vascular disorder, ischemic reperfusion ocular disorder, ischemic reperfusion skin disorder.
- infectious diseases to which the composition for preventing and treating free radical disease of the present invention is applied include bacterial infections such as enteric bacterial infections caused by Escherichia coli, hepatitis due to hepatitis virus, acquired immune deficiency syndrome due to HIV (AI DS), colds caused by rhinoviruses, influenza infections caused by influenza viruses, fungal infections such as candidiasis caused by Candida fungi, and parasitic infections such as malaria caused by malaria parasites.
- bacterial infections such as enteric bacterial infections caused by Escherichia coli, hepatitis due to hepatitis virus, acquired immune deficiency syndrome due to HIV (AI DS), colds caused by rhinoviruses, influenza infections caused by influenza viruses, fungal infections such as candidiasis caused by Candida fungi, and parasitic infections such as malaria caused by malaria parasites.
- other free radical diseases that are targets of the composition for preventing and treating free radical diseases of the present invention include vascular thrombosis, anemia, ischemia, and vascular sclerosis associated with the above organs of the present invention.
- Vasoconstriction Vasoconstriction, blood flow rate (OBAYASH I, PROC. SOC. EXP. BI OL. WED., 1 9 6, 1 9 6, 1 64-1 6 9, 1 9 90) etc.
- OBAYASH I PROC. SOC. EXP. BI OL. WED., 1 9 6, 1 9 6, 1 64-1 6 9, 1 9 90
- Examples include, but are also effective for, damage to cells and tissues associated with physical deterioration and cessation of the disease, illness and disease and insufficiency of organs including blood vessels.
- free radical diseases targeted by the composition for preventing and treating free radical diseases of the present invention include oxygen deficiency caused by a decrease in oxygen pressure in blood vessels and chemicals such as pesticides and carbon monoxide poisoning. It can also include temporary oxygen deficiency of tissue or oxygen deficiency of tissues due to substances, and is sent to cells or tissues with normal or close blood flow by appropriate treatment or event such as blood transfusion. Examples include damage to cells and tissues that are found at the time of detection, disease and insufficiency of organs including blood vessels and blood vessels, and these are also effective.
- the composition for preventing and treating free radical disease of the present invention is particularly effective, and is a specific example of the ischemic reperfusion disease of the free radical disease to be targeted.
- Examples include ischemia-reperfusion myocardial injury (NAR I TA. W. J, J. LAB. CL I N. MED., 1 1 0, 1 5 3— 1 5 8, 1 9 8 7, Sm ith, L. L. Phil.Trans.R.Soc.Lond., 3 1 1, 6
- VIER VIER
- AM S TERDAM 1 9 9 0, Nakahama, Liver, 32: 1 1 1 1 0-1 1 2 3, 1 9 9 1, Takekawa, Liver, 3 0: 4 5 9— 4 67, 1 9 8 9, Shirasugi, Nissho Gaijin, 2 6: 3 5 8, 1 9 9 3) Ischemia-reperfusion kidney injury, ischemia-reperfusion knee injury (ISAJI, S .: MIE MED. J., 3 5: 1 09-1 2 3, 1 98 5), ischemic reperfusion gallbladder disorder (TAOKA, GAS TROENT.
- JP N., 2 6: 6 3 3-644, 1 9 9 1) ischemic reperfusion circulatory system Disorders, ischemia-reperfusion digestive disorders (Iwai, Nisshokai, 87: 1 6 6 2-1 6 6 9, 1 990, NA I TO, Y., FREE RED. RE
- composition for preventing and treating free radical disease of the present invention is also effective for the following various disorders induced by active oxygen.
- Specific examples include Behcet's disease, radiation damage, side effects of anticancer drugs, bacterial shock, cachexia, autoimmune disease, burns, herpes virus, adult T cell leukemia, thioredoxin syndrome, traumatic shock, Examples include fungal amyotrophic lateral sclerosis and asexual myocardial infarction.
- the composition for preventing and treating free radical disease of the present invention has low toxicity and can be administered orally or parenterally to a mammal containing human.
- the composition for preventing and treating free radical disease of the present invention is not particularly limited, and is an oral administration agent, an infusion solution, a tablet, a powder, a liquid suppository, an external preparation, an ointment, a patch, an eye drop, an intravenous injection, a powder, Granules, tablets, dragees, capsules, pills, Suspensions, liquids, ampoules, injection solutions, isotonic solutions, etc. can be mentioned, and they can be applied to other forms of pharmaceutical products.
- the main active ingredients are fullerenes: cyclodextrin-containing C 60 fullerene, hydroxylation rate of 50 / mol ⁇ fullerene or more — hydroxylated hydroxyl group with directly bonded OH groups C 60 and C 70 fullerene
- the metal salt include sodium salt, potassium salt, calcium salt, and magnesium salt.
- It can be formulated as a pharmaceutically acceptable inert carrier or as a mixture with diluted opium or other pharmacological agents, or in dosage unit form.
- the main component of the present invention may be used as a cyclodextrin or a complex with maltocycle cyclodextrin for the purpose of increasing solubility in water to promote absorption and enhancing pharmacological activity.
- composition for preventing and treating free radical disease of the present invention is usually used orally or parenterally as a pharmaceutical composition comprising these active ingredients mixed with a pharmacologically acceptable carrier or excipient. It is done.
- each active ingredient is made into an aqueous solution beforehand, each active ingredient is freeze-dried to form a solid mixture, and each active ingredient made into an aqueous solution is freeze-dried to make each solid form.
- One of the active ingredients is an aqueous solution and another active ingredient is freeze-dried to form a solid form, and the form of a kit or the like in which each active ingredient is separately formulated.
- the present invention was listed in the twelfth revised Japanese Pharmacopoeia Heisei 3 (Shishin Shoten), etc., which can be pharmaceutically acceptable if desired according to known pharmaceutical manufacturing methods. Diluents, excipients, etc. can be mixed and administered as a single agent.
- each active ingredient can be pharmaceutically acceptable if desired. It is also possible to formulate it using a diluent, excipient, etc., and administer it as a single agent using a working diluent. Furthermore, as described above, a separate formulation is used as a kit, and these are administered separately, at the same time, or with a time difference, to the same subject by the same route or different routes. It can also be.
- composition of the present invention is a solution
- a water-soluble agent for example, distilled water
- a water-soluble preparation for example, physiological saline, Ringer's solution, etc.
- an oily solvent for example, sesame oil, corn oil
- Olive oil etc.
- a solubilizer eg, sodium salicylate, sodium acetate, etc.
- a buffer eg, sodium citrate, glycerin, etc.
- an isotonic agent eg, sugar, etc.
- a stabilizer eg, sugar
- Additives such as human serum albumin, polyethylene glycol, etc.), preservatives (eg, benzyl alcohol, phenol, etc.), soothing agents (eg, benzalkonium chloride, pro-in hydrochloride, etc.) can also be used.
- Pharmacologically and pharmaceutically acceptable additives as desired e.g. diluents, excipients, binders, disintegrants, colorants, stabilizers, extenders, wetting agents, surfactants, lubricants
- a mixture of a mixture, a dispersant, a buffering agent, a buffering agent, a flavoring agent, a flavoring agent, a flavoring agent, a preservative, a solubilizing agent, a solvent, a coating agent, a sugar coating agent, etc. it can.
- the diluent used for the preparation of the composition for preventing and treating free radical disease of the present invention is pharmaceutically acceptable, but means a material other than the inventive compound of this application, and is solid, semi-solid, liquid or ingested. Capsules that can be used may be used, and various types of capsules can be used.
- the composition for preventing and treating free radical disease obtained by the present invention may be produced by any known method.
- the active ingredient is mixed with a diluent, for example, into granules, and then the composition is prepared. It can also be formed into tablets, for example.
- Parenteral preparations should be sterile and, if necessary, isotonic with blood. Parenteral administration includes administration by injection (including, for example, intramuscular intravenous infusion) and transanal (suppository).
- composition of the present invention itself can be a cancer metastasis inhibitor, fullerenes or salts thereof which are active ingredients in preparations and compositions are generally used.
- compositions for oral administration further include tablets, pills, granules, powders, capsules, syrups, emulsions, suspensions, and sprays.
- Such a composition is produced by a method known per se, and lactose, starch, sucrose, steamonoester magnesium and the like are used as a carrier or an excipient.
- injections, suppositories, patches, eye drops, external preparations, etc. can be used, for example, intravenous infusions, subdermal injections, intramuscular injections It is used as a drug and infusion.
- the injection is usually provided in a suitable ampoule.
- dosage forms include rectal suppositories and vaginal suppositories
- external preparations include ointments, nasal injections, and transdermal preparations.
- the composition of the invention of this application can be made into a solid, semi-solid or liquid external preparation according to a method known per se.
- the composition of the invention of this application is used as it is or an excipient (eg, glycol, mannitol, starch, microcrystal, cellulose, etc.), a thickener (eg, natural) Gums, cellulose derivatives, acrylic polymers, etc.) are added and mixed to obtain a powdery composition.
- an excipient eg, glycol, mannitol, starch, microcrystal, cellulose, etc.
- a thickener eg, natural Gums, cellulose derivatives, acrylic polymers, etc.
- liquids are almost the same as in the case of injections, and should be oily or aqueous suspensions.
- an aqueous or oily gel or an ointment is preferred.
- pH regulators eg, carbonic acid, monoester, citrate, hydrochloric acid, sodium hydroxide, etc.
- preservatives eg, paraoxybenzoate
- Perfume esters, chlorobutanol, benzalkonium chloride, etc. may be added.
- the composition of the invention of this application can be made into an oily or aqueous solid, semisolid or liquid suppository.
- the concentration of fullerenes to be blended in the composition of the present invention is 0.001 to 100 ppm based on the total weight of the composition for preventing and treating free radical diseases of the present invention. In view of good solubility in blood, 0.1 to: I 0 0 ⁇ ⁇ m is preferable.
- substances that can be incorporated into the composition for preventing and treating free radical diseases of the present invention for the purpose of stabilizers, active active agents and the like include metolazol, etopside, cholic acids, dimethylsulfol, which are generally used as additives.
- Water-soluble polymer compounds such as cisids, adesosine phosphates, polyethylene glycols, polypropylene glycols, inorganic salts such as sodium chloride, chlorinated lithium, magnesium chloride, citrate, malic acid, phosphoric acid, edetic acid, Selected from organic acids such as oxalic acid, lactic acid, butyric acid, acetic acid, ascorbic acid, erythorbic acid, sialic acid and amino acids and their organic acid salts, or polyhydric alcohols such as propylene glycol, butylene glycol and glycerin One or a mixture of two or more may be mentioned.
- the cholic acids are selected from bile acids, dehydrocholic acids, deoxycholic acids or their alkaline earth metal salts such as sodium and potassium.
- the adenosine phosphate is selected from adenosine phosphates such as adenosine mono5′3 phosphate, adenosine mono5′2 phosphate, and adenylate.
- oral preparations, external preparations and injection preparations are desirable from the viewpoint of simplicity of administration and effects.
- the drug of the present invention can be formulated by combining the above pure substance or a mixture thereof with a known pharmaceutical carrier, and has the highest effect and is easy to administer. Is preferred.
- a fullerene water adduct or a crystal water adduct is an anhydride thereof. It is useful because it has a higher solubility in water.
- the water content or water content of the fullerenes or crystal water adducts of the present invention is not particularly limited, but in order to maintain better solubility, the water content is 1% to 50% by weight, More preferably 5% to 20% by weight, and in the case of crystal water, a water adduct or crystal water adduct of fullerenes holding water molecules in the range of 1 to 20 hydrates, more preferably 1 to 10 hydrates is desirable. .
- the dosage of fullerenes of the present invention will be described. Although it varies depending on symptoms, age, sex, body weight, dosage form, dosage form, for example, oral administration, suppository administration, external preparation, etc. 0.001 to 8500 mg per kg. Preferably in the range of l-100 mg. In addition, in the case of intravenous injection or infusion, it is usually possible to administer 0.025 to 200 mg, preferably 0.25 to 100 mg, in 1 or several divided doses per body weight per day for an adult.
- the injection of the present invention is intravenously or instilled into a vein or the like at 0.1 to 50 cc per kg of human body weight so that the total amount of dissolved substances in the injection solution is 1 gZkg / hour or less.
- the dose of fullerenes of the present invention varies depending on the preparation type and administration method. Usually, 1 / mgZkg body weight / day to lOmg / kg body weight Zday is administered once or divided into several times.
- composition for the prevention and treatment of free radical disease of the present invention may be added by adjusting the kind and amount of the fullerenes and cleavage fullerenes and derivative salts thereof of the present invention, or the fullerenes of the present invention.
- an additive capable of adjusting the osmotic pressure to the cleaved fullerenes and their derivative salts, the permeability of fullerenes, cleaved fullerenes and their derivative salts, which are the main components of the solution, to tissue cells is increased. A greater effect can be obtained.
- Additives that can adjust the osmotic pressure include inorganic salts such as sodium chloride and potassium chloride, organic acids such as ATP, malic acid and citrate or organic acid salts such as sodium, sugars such as glucose and fructose, etc.
- inorganic salts such as sodium chloride and potassium chloride
- organic acids such as ATP, malic acid and citrate or organic acid salts such as sodium
- sugars such as glucose and fructose, etc.
- physiologically acceptable additive such as one or two or more composites selected from the above.
- Antioxidants include vitamin B, L-ascorbic acid, tocopherol, and L-ascorbic acid-2-phosphoric acid and other saccharoses such as L-ascorbic acid, ubiquinone, uric acid, cystis , Dalyuthione, Dalthathione Peroxylase, SOD, Quenic Acids, Phosphoric Acids, Polyphenols, Sodium Bisulfite, Sodium Bisulfite, Erythorbic Acid, Sodium Erythorbate, Dilauryl Thiodipropioate, Kotocoli Enol, Lipoic acid, Trilbiguanide, Nordihydroguaiaretinic acid, Parahydroxylanisol, Ptylhydroxanisol, Dibutylhydroxytoluene, Ascorbyl stearate, Ascorbyl palmitate, Octyl gallate,
- Fullerenes which are the active ingredients of the composition for preventing and treating free radical diseases of the present invention, inhibit and stabilize such antioxidants, particularly ascorbic acid, at the time of production, storage period, digestion. There is little degradation over time in the tube. In addition, when normal ascorbic acid is taken into the living body, it is degraded by radicals contained in the living body, particularly food in the digestive tract, etc., and is hydrolyzed and deactivated before reaching the target cell. Fullerenes, which are active ingredients, are stable and are absorbed by the body through nutrient-absorbing cells without being inactivated.
- fullerenes exhibit extremely high cell absorbability.
- the concentration of intracellular ascorbic acid can be increased up to about 30 times as compared with fullerene and about twice as high as that of ascorbic acid.
- the composition for preventing and treating free radical disease of the present invention can exert the cancer metastasis inhibitory action that is not recognized by ascorbic acid as described above.
- cancer cells Because of its dynamic performance, cancer cells can invade blood vessels from the lesion and migrate to a wide range of organs and proliferate. For this reason, the life extension period is remarkably shortened.
- the anti-tumor action of the fullerenes of the present invention can exert a cancer metastasis inhibitory action, particularly by inhibiting the ability of cancer cells to migrate from the lesion to the vascular endothelium and consequently inhibiting cancer metastasis. It has been confirmed. It has been found that cancer cells administered with the fullerenes of the invention of this application show a very low infiltration rate into the vascular endothelium. This action has been confirmed to be unique to fullerenes.
- fullerenes which are active ingredients of the composition for preventing and treating free radical disease of the present invention, inhibit and stabilize oxidative degradation of ascorbic acid.
- fullerenes exhibit extremely high cell absorptivity and can efficiently increase intracellular ascorbic acid concentration, so that the antitumor action of ascorbic acid can be maximized.
- the antitumor action of fullerenes is thought to exert its anticancer action, particularly by inhibiting the invasion of tumor cells into the vascular endothelium and consequently inhibiting cancer metastasis.
- the composition for preventing and treating free radical diseases of the present invention can be applied to pharmaceuticals, quasi drugs, cosmetics, and functional foods.
- the composition of the present invention can take all dosage forms such as powders, liquids, tablets, gels, emulsions, capsules, etc., specifically, drinks, injections, ointments, suppositories, external preparations. Can be applied. More specifically, it can be used as products such as lotions, milk lotions, creams, packs, shampoos, rinses, hair restorers, hair nourishing agents, hair dyes, hair conditioners, scouring, gargles, bathing agents, etc. It is not particularly limited.
- Cosmetics in the present invention include, for example, makeup cosmetics such as foundation, white powder, wisdom shadow, eyeliner, eyebrow, teak, lipstick, nail color, etc .; emulsion, cream, lotion, calamine lotion, sunscreen agent, suntan agent, After shave lotion, Basic cosmetics such as sachets, rinses, conditioners, hair colors, hair tonics, set agents, hair nourishing agents, permanent agents, etc .; pode powder, It is classified into deodorant, hair remover, seggen, body shampoo, bath preparation, hand soap, perfume, etc. and can be used as cosmetics for each.
- the dosage form of the present invention is not particularly limited, and is conventionally known such as a two-layered, water-in-oil emulsion, oil-in-water emulsion, jewel, spray, mousse, oil, solid, sheet, powder, etc.
- the dosage form can be used.
- the present invention comprises a fullerene having high radical scavenging activity in vivo as an active ingredient as a main component, so that it is stable during preparation and storage, and is safe and effective with few side effects on the living body. It was possible to provide a composition for preventing and treating free radical diseases.
- the solution was sterilized and filtered through a sterilizing filter for producing injection solution, and an injection solution was produced as a preventive / remedy for intravenous free radical disease of the present invention.
- Hydroxylation rate 8 7% (mol conversion) C 60 Fullerene and hydroxylation rate 6 1% (molar equivalent) of hydroxylated C 70 fullerene uniformly mixed at a weight ratio of 8: 2 was completely dissolved in 10 cc cc pharmaceutical Ringer's solution at a concentration of 5 ppm and then injected. Sterile filtration was performed with a sterilizing filter for liquid production, and an injection solution was produced as a free radical disease preventive / remedy for intravenous injection according to the present invention.
- Example 5 Water-soluble external preparation and cosmetic lotion
- Example 1 of the present invention was intravenously administered to rats, and as a control group, only Ringer's solution was injected in the same manner as in the test group.
- free radical-dependent chemiluminescence in peripheral blood was measured by chemiluminescence before the experiment, a significant increase in free radicals was confirmed immediately after reperfusion.
- Rat crown as test area in advance Arterial block 1 5 mg / kg of the free radical disease prevention and treatment composition of the present invention, which is 5 mg / kg, is administered intravenously to rats as a control group, and only Ringer's solution is used as a control group in the same manner as in the test group. Injected into.
- the blood amylase level in the control group was significantly higher than the level before blocking, and up to 60 00 U / dl individuals were observed.
- the blood amylase level in the test group to which the injection of the present invention was administered was 100 0 U / d 1 at the maximum, and a slight amylase increased tendency was observed compared to the normal state before blockade. However, it was significantly lower than the control group, and the effect of the composition for preventing and treating free radical disease of the present invention on the knee disease was proved.
- Example 4 After blocking the rat coronary artery for 20 minutes and resuming blood flow for 60 minutes, a renal disease model that damaged the kidney tissue was created, and the mean urinary protein was measured before coronary artery blockage and after resumption of blood flow for 5 days did.
- free radical-dependent chemiluminescence in peripheral blood was measured by chemical luminescence before the experiment, a significant increase in free radicals was confirmed immediately after resumption of blood flow.
- 5 mkg of the injection of Example 4 was intravenously administered to the rat 15 minutes before blockage of the rat coronary artery, and only Ringer's solution was injected as a control group in the same manner as the test group.
- the urinary protein level in the control group was significantly higher than the level before the blockade, and the renal disease was clearly observed.
- the urinary protein level in the administered test group showed a slight increase in urinary protein compared to the normal state before blocking, but it was significantly lower than that in the control group.
- the cell necrosis index of the heart, liver, kidney, knee and gallbladder is 45 C. a Obtained by autoradiograph image analyzer.
- the cell necrosis index of the heart, liver, kidney, knee and gallbladder is 45 C. a Obtained by autoradiograph image analyzer.
- In the control rats delayed cell death in which many cells were necrotized in each organ after ischemia was observed, but in the mice injected with the injection of the present invention (10 mice per group), necrosis of each cell was observed. Has been confirmed to be remarkably prevented.
- the same amount of the pharmaceutical composition of the present invention was injected once a day for 5 days, dissected after 10 days, and the cell necrosis index of the heart, liver, kidney, knee and gallbladder was determined as 45. It was determined by C a autoradiography / image analyzer. In the control rats, when seen with a 45 Ca autoradiography image analyzer, delayed cell death in which many cells were killed in each organ after ischemia was observed, but the injection solution of the present invention was injected. In mice (8 mice per group), it was confirmed that the death of each cell was remarkably prevented.
- Skin diseases that are said to involve free radicals, pigmentation due to sunlight, skin folds, alveolar pyorrhea in the oral cavity, seborrhea of skin tissue, acne, Males and females suffering from hair loss 5 1 3 out of 3 2 2 4 Only mannitol as a control group and the remaining 2 8 9 patients as a test group
- the water-soluble external preparation of Example 5 was used in the morning and evening 2 times a day, 5 cc (—l O cc per day) was applied for 3 months or only in the case of alveolar pyorrhea, and the mouth was rinsed for 3 minutes with mouthwash and the symptoms were recorded every other week.
- M i 1 1 1 i-Q registered trademark
- fullerene polyester two hydroxylations of fullerene hydroxide are esterified with acetic acid, and for Na and Na-K salts, two hydroxyl groups are esterified with acetic acid. These two hydroxyl groups were substituted with Na or Na and K.
- the powders of the present invention were produced by mixing and pulverizing with the formulation (% by weight) shown in Table 3.
- Sterilized compounds listed in Table 1 (Prescription Nos. 1 to 10) 1 g each is aseptically dissolved in 5% glucose solution for injection to 10 Om 1, filtered through a 0.2 tm membrane filter, and 10 ml injected An injection was obtained by filling the ampoule.
- Sterilized compounds shown in Table 1 above (Formulation Nos. 1 to 10) 5 g each and 5% glucose solution for infusion 500 ml 1 were dissolved, followed by filtration through a 0.2 mm membrane filter to obtain an infusion solution.
- a powder was obtained by mixing 1 g of each of the compounds described in Table 1 (prescription numbers 1 to 10) and 10 g of crystalline lactose.
- Oral syrups were obtained by suspending the compounds described in Table 1 (prescription numbers 1 to 10) in an oral syrup solution.
- An external preparation (ointment) of the composition for the prevention and treatment of free radical disease of the present invention was produced by a conventional method according to the prescription in Table 5 below.
- liquid preparation for the free radical disease prevention / treatment composition of the invention of this application was produced by a conventional method.
- PVP Fullerene (P VP molecular weight 60, 000) 5. 0 Methyl paraoxybenzoate 0.1 Sodium citrate 0. 5 Quenic acid 0. 05
- Test example 1 Stability test
- PVP .fullerene PVP molecular weight 60, 000
- fullerene mono Table 7 shows the difference in stability between esters and fullerene monoester salts in aqueous solution (10-day room temperature storage test). It can be seen that fullerenes are stable regardless of the type, but ascorbic acid is easily hydrolyzed in purified water over time.
- the stability was evaluated by allowing a 0.1% aqueous solution (purified water) of the above substance to stand at room temperature for 10 days and measuring the residual ratio by HPLC.
- Test example 2 Intracellular absorbability (intracellular transport) test
- Test example 3 Cell mobility (cell tactility) test
- the cancer cells were preliminarily administered with ascorbic acid for 18 hours, and the fullerenes of the invention of this application having prescription numbers 1 to 13 in Table 1 above.
- the number of infiltrating cancer cells in the case of no administration was 12400, but in any case, the number decreased significantly.
- PVP ⁇ fullerene PVP molecular weight 60,000
- Rats spontaneous breast cancer cells were implanted subcutaneously in the back of spontaneously hypertensive rats (S HR rats) (5 rats per group), and the rats were sacrificed 35 days later. The number of lung weights and the number of colonies formed was measured, and the degree of lung metastasis of SST-2 was observed.
- the compound administration group of the invention of this application of prescription No. 1 in Table 1 above is 50 and from 7 days before transplantation to 34 days after transplantation.
- W 10 Omg / rat was orally administered and injected subcutaneously, and subcutaneous tumor weight, lung weight, and number of metastatic colonies were compared with the untreated control group. The results are shown in Table 8.
- the compound administration group of the present invention has an action of suppressing metastasis to the lung.
- Rats spontaneous breast cancer cells (S ST-2) were transplanted subcutaneously in the back of spontaneously hypertensive rats (S HR rats) (5 rats in each group) 1 X 1 0 0, 0 0 0 cells 3 5 days Later, the rats were sacrificed to determine the number of lung weights and colony formation, and the degree of lung metastasis of SST-2 was observed.
- the compound administration group of the invention of this application of prescription No. 1 in Table 1 above was tested for carrier administration and combined administration with known anticancer agents shown in Table 9. From the 7th day before transplantation to the 34th day after transplantation, the compound of the invention of this application 5 Omg / day / rat.
- Test Example 6 Evaluation of inhibitory effect on mouse skin cancer metastasis
- PVP * fullerene P VP molecular weight 60, 0 00
- the cancer wetness test was conducted using 2 ml). In the test, P VP fullerene was administered immediately before cancer cells infiltrated into the reconstituted basement membrane, and PVP fullerene was administered 1 hour before cancer cells infiltrated into the reconstituted basement membrane. Then, the cells were gently agitated for 1 hour to prevent cell adhesion, and were then infiltrated with “pretreatment hr”.
- Matrigel (0.1 2 mg / m 1) 40 ⁇ , I was used. Compared to the case of non-administration and the case of administering only PVP (molecular weight 60, 00). The results are shown in Fig. 2.
- composition for preventing and treating free radical disease of the present invention as described above.
- radical disease drugs that use conventional antioxidants as the main agent, which are easily oxidized and difficult to maintain quality after the formulation process or formulation, the activity is not lost in the formulation and in vivo. It is stable, safe and has almost no side effects, and has an excellent free radical scavenging activity.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05770604A EP1834637A4 (en) | 2004-12-07 | 2005-08-05 | COMPOSITION FOR THE PREVENTION / TREATMENT OF DISEASES THROUGH FREE RADICALS |
US11/792,520 US20080206222A1 (en) | 2004-12-07 | 2005-08-05 | Preventive/Therapeutic Composition For Free Radical Disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004/354271 | 2004-12-07 | ||
JP2004354271A JP2006160664A (ja) | 2004-12-07 | 2004-12-07 | フリーラジカル疾患予防治療用組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006061925A1 true WO2006061925A1 (ja) | 2006-06-15 |
Family
ID=36577755
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/014798 WO2006061925A1 (ja) | 2004-12-07 | 2005-08-05 | フリーラジカル疾患予防治療用組成物 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080206222A1 (ja) |
EP (1) | EP1834637A4 (ja) |
JP (1) | JP2006160664A (ja) |
KR (1) | KR20070112762A (ja) |
CN (1) | CN101098684A (ja) |
WO (1) | WO2006061925A1 (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008109033A1 (en) * | 2007-03-02 | 2008-09-12 | Luna Innovations Incorporated | Steroid derivatives of fullerenes |
EP1992339A1 (en) * | 2007-05-18 | 2008-11-19 | Saeed Sarkar | Use of a magnesium isotope for treating hypoxia and a medicament comprising the same |
WO2008063157A3 (en) * | 2006-10-25 | 2009-03-19 | Us Gov Health & Human Serv | A nanoparticle-based anticoagulant |
US7879996B2 (en) | 2007-05-18 | 2011-02-01 | Saeed Sarkar | Water soluble compounds |
US8834932B2 (en) | 2011-12-19 | 2014-09-16 | Industry Technology Research Institute | Anticoagulant-conjugated carbon nanocapsule, antithrombotic agent containing thereof |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1867337B1 (en) | 2005-03-23 | 2014-10-01 | St. Marianna University School of Medicine | Medicinal composition comprising a fullerene for treating/preventing motor organ disease involving cartilage degeneration |
CN100443120C (zh) * | 2006-07-07 | 2008-12-17 | 中国科学院长春应用化学研究所 | 水溶性环糊精-c60超分子包合物的制备方法 |
JP4899154B2 (ja) * | 2006-09-21 | 2012-03-21 | 独立行政法人産業技術総合研究所 | 中空ナノ炭素集合体並びに一重項酸素消去剤、化粧剤、皮膚ガン抑制剤及び退色防止剤 |
JPWO2008047880A1 (ja) * | 2006-10-20 | 2010-02-25 | 学校法人 聖マリアンナ医科大学 | 関節リウマチ治療薬 |
EP2259785B1 (en) * | 2008-03-03 | 2015-12-23 | Luna Innovations Incorporated | Fullerene therapies for inflammation |
JP2011001302A (ja) * | 2009-06-19 | 2011-01-06 | Seiji Motojima | 炭素繊維−糖質複合形状体及びその製造方法、炭素繊維−糖質複合形状体含有親水性材料並びに炭素繊維−糖質複合形状体含有サプリメント |
KR20120007139A (ko) * | 2010-07-14 | 2012-01-20 | 주식회사 파미니티 | 탄소나노튜브를 유효성분으로 함유하는 뇌질환 예방 또는 치료용 조성물 |
TWI431002B (zh) | 2011-05-30 | 2014-03-21 | Ind Tech Res Inst | 富勒烯衍生物與光電元件 |
TN2011000327A1 (en) | 2011-06-30 | 2012-12-17 | Fathi Moussa | Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals |
WO2014129513A1 (ja) * | 2013-02-19 | 2014-08-28 | 国立大学法人大阪大学 | 潰瘍性大腸炎の予防または治療剤と新規フラーレン誘導体 |
US20160331698A1 (en) * | 2014-01-13 | 2016-11-17 | University Of Central Florida Research Foundation, Inc. | Fullerene compounds as antioxidant therapy |
CN104069129A (zh) * | 2014-06-24 | 2014-10-01 | 苏州大德碳纳米科技有限公司 | 一种治疗牛皮癣和皮炎的外涂液及其制备方法与应用 |
JP2016094356A (ja) * | 2014-11-12 | 2016-05-26 | 学校法人君が淵学園 | 慢性腎不全の予防または治療のための経口摂取物 |
CN105267238A (zh) * | 2015-10-15 | 2016-01-27 | 北京福纳康生物技术有限公司 | 一种预防和/或治疗骨髓抑制的微纳材料及其应用 |
CN105596368B (zh) * | 2016-02-01 | 2019-04-16 | 北京福纳康生物技术有限公司 | 一种富勒烯橄榄油组合物及其在治疗帕金森病中的应用 |
CN107753510A (zh) * | 2016-08-15 | 2018-03-06 | 北京福纳康生物技术有限公司 | 富勒烯在制备药物中的用途以及预防或治疗缺铁性贫血的药物 |
CN106421923A (zh) * | 2016-09-23 | 2017-02-22 | 中国人民解放军军事医学科学院基础医学研究所 | 一种可注射性抗氧化水凝胶及其制备方法 |
WO2018113094A1 (zh) * | 2016-12-19 | 2018-06-28 | 北京福纳康生物技术有限公司 | 富勒烯结构在制备治疗糖尿病及其并发症的药物中的应用 |
CN108201541A (zh) * | 2016-12-19 | 2018-06-26 | 北京福纳康生物技术有限公司 | 富勒烯结构在制备增强胰岛素敏感性的药物中的应用 |
CN108201542A (zh) * | 2016-12-19 | 2018-06-26 | 北京福纳康生物技术有限公司 | 油溶性富勒烯在制备治疗糖尿病并发症的药物中的应用 |
CN108771685A (zh) * | 2016-12-19 | 2018-11-09 | 中国科学院化学研究所 | 水溶性富勒烯结构在制备治疗糖尿病的药物中的应用 |
CN106692189A (zh) * | 2017-01-25 | 2017-05-24 | 中国科学院化学研究所 | 一种保护肝脏的组合物 |
WO2018156923A1 (en) * | 2017-02-23 | 2018-08-30 | LivePet, LLC | Lipofullerene-saccharide conjugates and their use as antimetastatic agents for the inhibition of mammalian neoplasms |
CN108969536A (zh) * | 2017-05-31 | 2018-12-11 | 北京福纳康生物技术有限公司 | 水溶性富勒烯结构在制备治疗肥胖症的药物中的应用 |
CN109925320A (zh) * | 2017-12-19 | 2019-06-25 | 中国科学院化学研究所 | 水溶性富勒烯在制备pi3k-akt调节剂中的应用 |
CN109925321A (zh) * | 2017-12-19 | 2019-06-25 | 中国科学院化学研究所 | 水溶性富勒烯结构在制备ampk调节剂中的应用 |
CN111317745B (zh) * | 2018-12-13 | 2021-09-07 | 中国科学院化学研究所 | 水溶性富勒烯结构在制备治疗帕金森病的药物中的应用 |
CN110151786B (zh) * | 2019-05-06 | 2021-11-30 | 天津百纳生物技术有限公司 | 纳米碳颗粒在制备治疗口腔溃疡的药物中的应用及该药物 |
CN111419793A (zh) * | 2020-04-29 | 2020-07-17 | 上海紫河生物科技有限公司 | 一种含富勒烯及其衍生物的滴眼液及其制备方法 |
CN112741842B (zh) * | 2021-02-02 | 2022-07-15 | 中国科学院化学研究所 | 口服富勒烯材料在制备预防和/或治疗心肌缺血再灌注损伤或缺血性心脏病药物中的应用 |
CN113648331A (zh) * | 2021-08-30 | 2021-11-16 | 中国科学院化学研究所 | 口服富勒烯材料在制备治疗胃溃疡药物中的应用 |
CN113730367B (zh) * | 2021-09-28 | 2022-12-02 | 海南海灵化学制药有限公司 | 一种恩替卡韦片的制备工艺 |
CN114042085A (zh) * | 2021-11-12 | 2022-02-15 | 中国科学院化学研究所 | 一种治疗皮肤创伤的药物组合物及其制法 |
WO2023107144A1 (en) * | 2021-12-10 | 2023-06-15 | Peter Butzloff | Nitric oxide c60-gsh-atp and use |
CN114732830A (zh) * | 2022-04-19 | 2022-07-12 | 青岛惠诺德生物科技有限公司 | 一种c60油在制备口服药品或口服保健品中的应用及产品活性检测方法 |
CN114903916B (zh) * | 2022-04-28 | 2024-01-02 | 中国科学院化学研究所 | 口服富勒烯结构及制剂、及其防治类风湿性关节炎的应用 |
CN115429712B (zh) * | 2022-09-02 | 2024-01-23 | 广东粤港澳大湾区国家纳米科技创新研究院 | 一种多肽和富勒烯共输送纳米组合物、其制备方法及应用 |
CN115645437A (zh) * | 2022-09-26 | 2023-01-31 | 中国科学院化学研究所 | 富勒烯制剂在制备治疗肠道癌症的药物中的应用 |
CN115624624B (zh) * | 2022-12-22 | 2023-03-21 | 南京智正医药科技有限公司 | 一种富勒烯衍生物在制备治疗酒精性肝病药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002504525A (ja) * | 1998-02-25 | 2002-02-12 | アクシーバ・ゲーエムベーハー | デンドリマーフラーレン誘導体、その調製方法、および神経保護剤としての使用 |
JP2004231595A (ja) * | 2003-01-31 | 2004-08-19 | Mitsubishi Chemicals Corp | 水酸化フラーレンを含む神経細胞保護剤 |
JP2004250690A (ja) * | 2003-01-27 | 2004-09-09 | Mitsubishi Corp | 抗酸化組成物と外用組成物 |
JP2004292443A (ja) * | 2003-03-10 | 2004-10-21 | Mitsubishi Corp | 抗c型肝炎ウイルス剤と抗hiv剤 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5648523A (en) * | 1995-10-26 | 1997-07-15 | Chiang Long Y | Fullerene derivatives as free-radical scavengers |
US6949660B2 (en) * | 1995-10-26 | 2005-09-27 | Seth Nanotechnology, Incorporated | Chiral (1pyrrolino) fullerene derivatives |
AU2001289127A1 (en) * | 2000-09-21 | 2002-04-02 | Long Y. Chiang | Tumor treatment |
JP4293735B2 (ja) * | 2001-01-19 | 2009-07-08 | 三栄源エフ・エフ・アイ株式会社 | フラーレン誘導体およびそれからなる組成物 |
US6452037B1 (en) * | 2001-04-23 | 2002-09-17 | Long Y. Chiang | Multioligonanilinated fullerenes |
US6620816B2 (en) * | 2001-04-26 | 2003-09-16 | Bristol-Myers Squibb Company | Method for treating tumors by the administration of tegafur, uracil, folinic acid, and cyclophosphamide |
US7145032B2 (en) * | 2002-02-23 | 2006-12-05 | Washington University | Therapeutic malonic acid/acetic acid C60 tri-adducts of buckminsterfullerene and methods related thereto |
US20030162837A1 (en) * | 2002-02-23 | 2003-08-28 | Dugan Laura L. | Carboxyfullerenes and methods of use thereof |
WO2004007426A1 (en) * | 2002-07-17 | 2004-01-22 | Chiang Long Y | Fullerene compounds |
JP2004292426A (ja) * | 2003-03-10 | 2004-10-21 | Mitsubishi Corp | 抗菌剤と抗ガン剤 |
EP1615609A2 (en) * | 2003-04-10 | 2006-01-18 | C Sixty, Inc. | Fullerene compositions for ameliorating dermatological conditions |
RU2236852C1 (ru) * | 2003-06-23 | 2004-09-27 | Закрытое акционерное общество "ДЕСКО" | Средство для ингибирования репродукции оболоченных вирусов, способ его получения, фармацевтическая композиция и способ ингибирования вирусных инфекций |
US7163956B2 (en) * | 2003-10-10 | 2007-01-16 | C Sixty Inc. | Substituted fullerene compositions and their use as antioxidants |
AU2004299492B2 (en) * | 2003-12-15 | 2011-03-24 | Nano-C, Inc. | Higher fullerenes useful as radical scavengers |
-
2004
- 2004-12-07 JP JP2004354271A patent/JP2006160664A/ja active Pending
-
2005
- 2005-08-05 CN CNA2005800420878A patent/CN101098684A/zh active Pending
- 2005-08-05 WO PCT/JP2005/014798 patent/WO2006061925A1/ja active Application Filing
- 2005-08-05 KR KR1020077012856A patent/KR20070112762A/ko not_active Application Discontinuation
- 2005-08-05 US US11/792,520 patent/US20080206222A1/en not_active Abandoned
- 2005-08-05 EP EP05770604A patent/EP1834637A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002504525A (ja) * | 1998-02-25 | 2002-02-12 | アクシーバ・ゲーエムベーハー | デンドリマーフラーレン誘導体、その調製方法、および神経保護剤としての使用 |
JP2004250690A (ja) * | 2003-01-27 | 2004-09-09 | Mitsubishi Corp | 抗酸化組成物と外用組成物 |
JP2004231595A (ja) * | 2003-01-31 | 2004-08-19 | Mitsubishi Chemicals Corp | 水酸化フラーレンを含む神経細胞保護剤 |
JP2004292443A (ja) * | 2003-03-10 | 2004-10-21 | Mitsubishi Corp | 抗c型肝炎ウイルス剤と抗hiv剤 |
Non-Patent Citations (2)
Title |
---|
BOGDANOVIC G. ET AL: "Modulating activity of fullerol C60(OH)22 on doxorubucin-induced cytotoxicity.", TOXICOLOGY IN VITORO., vol. 18, no. 5, August 2004 (2004-08-01), pages 629 - 637, XP002991734 * |
See also references of EP1834637A4 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008063157A3 (en) * | 2006-10-25 | 2009-03-19 | Us Gov Health & Human Serv | A nanoparticle-based anticoagulant |
WO2008109033A1 (en) * | 2007-03-02 | 2008-09-12 | Luna Innovations Incorporated | Steroid derivatives of fullerenes |
EP1992339A1 (en) * | 2007-05-18 | 2008-11-19 | Saeed Sarkar | Use of a magnesium isotope for treating hypoxia and a medicament comprising the same |
US7879996B2 (en) | 2007-05-18 | 2011-02-01 | Saeed Sarkar | Water soluble compounds |
US8834932B2 (en) | 2011-12-19 | 2014-09-16 | Industry Technology Research Institute | Anticoagulant-conjugated carbon nanocapsule, antithrombotic agent containing thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2006160664A (ja) | 2006-06-22 |
KR20070112762A (ko) | 2007-11-27 |
EP1834637A1 (en) | 2007-09-19 |
CN101098684A (zh) | 2008-01-02 |
EP1834637A4 (en) | 2008-09-10 |
US20080206222A1 (en) | 2008-08-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006061925A1 (ja) | フリーラジカル疾患予防治療用組成物 | |
JP5737705B2 (ja) | 高分子化環状ニトロキシドラジカル化合物およびその使用 | |
JP5027885B2 (ja) | 水難溶性カンプトテシン誘導体のサブミクロンナノ粒子及びその製造方法 | |
Hou et al. | Phytosomes loaded with mitomycin C–soybean phosphatidylcholine complex developed for drug delivery | |
Koudelka et al. | Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect | |
JP2011512346A (ja) | クルクミンの可溶性錯体 | |
Ren et al. | A unique highly hydrophobic anticancer prodrug self-assembled nanomedicine for cancer therapy | |
Rahdar et al. | Pluronic F127/carfilzomib-based nanomicelles as promising nanocarriers: Synthesis, characterization, biological, and in silico evaluations | |
WO2001041757A1 (fr) | Composition pharmaceutique contenant de la cyclodextrine | |
Wang et al. | Investigating the crucial roles of aliphatic tails in disulfide bond-linked docetaxel prodrug nanoassemblies | |
Fu et al. | A novel redox-responsive ursolic acid polymeric prodrug delivery system for osteosarcoma therapy | |
TW201219370A (en) | Agent for regulating the formation of nitrogen monoxide | |
Gao et al. | A small molecule nanodrug consisting of pH-sensitive ortho ester–dasatinib conjugate for cancer therapy | |
US9956301B2 (en) | Complex of garcinol, cyclodextrin and method thereof | |
Zhang et al. | Rational design of tumor-selective prodrug nanoassemblies: Greatly improving the in vivo fate and tolerability of high-toxic cabazitaxel | |
Pan et al. | Dendron-polymer hybrid mediated anticancer drug delivery for suppression of mammary cancer | |
Fang et al. | Biodegradable self-assembly micelles significantly enhanced the solubility, biological stability and in vivo antitumor efficacy of Hexylselen | |
KR102314558B1 (ko) | 베네토클락스의 수용성 고분자 유도체 | |
JP2005272350A (ja) | 癌転移阻害剤 | |
JPH08291075A (ja) | 癌転移阻害剤 | |
CN114887076B (zh) | 一种具有化疗-免疫功能的混合三嵌段胶束及其制备方法和应用 | |
TWI727858B (zh) | 維奈托克(venetoclax)之水溶性高分子衍生物 | |
JP4287523B2 (ja) | 抗腫瘍剤 | |
JPH09301861A (ja) | ラジカル疾患用注射・点滴薬剤 | |
JP2009046450A (ja) | 抗がん剤へのヒアルロン酸添加 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 200580042087.8 Country of ref document: CN Ref document number: 1020077012856 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005770604 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11792520 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005770604 Country of ref document: EP |